**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 57029

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Endoscopy-based Kyoto classification score of gastritis related to pathological topography of neutrophil activity**

Toyoshima O *et al.* Kyoto score for neutrophil activity topography

Osamu Toyoshima, Toshihiro Nishizawa, Shuntaro Yoshida, Yoshiki Sakaguchi, Yousuke Nakai, Hidenobu Watanabe, Hidekazu Suzuki, Chizu Tanikawa, Koichi Matsuda, Kazuhiko Koike

**Osamu Toyoshima, Toshihiro Nishizawa, Shuntaro Yoshida,** Department of Gastroenterology, Toyoshima Endoscopy Clinic, Tokyo 157-0066, Japan

**Osamu Toyoshima, Shuntaro Yoshida, Yoshiki Sakaguchi, Yousuke Nakai, Kazuhiko Koike,** Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan

**Toshihiro Nishizawa,** Department of Gastroenterology and Hepatology, International University of Health and Welfare, Narita Hospital, Chiba 286-8520, Japan

**Shuntaro Yoshida, Yousuke Nakai,** Department of Endoscopy and Endoscopic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan

**Hidenobu Watanabe,** Department of Pathology, Pathology and Cytology Laboratory Japan, Tokyo 166-0003, Japan

**Hidekazu Suzuki,** Department of Gastroenterology and Hepatology, Tokai University School of Medicine, Kanagawa 259-1193, Japan

**Chizu Tanikawa, Koichi Matsuda,** Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan

**Koichi Matsuda,** Department of Computational Biology and Medical Sciences, Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo 108-8639, Japan

**Author contributions:** Toyoshima O, Nishizawa T, Yoshida S and Matsuda K designed the study; Toyoshima O and Yoshida S recruited patients; Toyoshima O analyzed data and wrote the manuscript; Nishizawa T edited the manuscript; Yoshida S, Sakaguchi Y, Nakai Y, TanikawaC, Matsuda K, Suzuki H and Koike K revised the manuscript; Watanabe H performed histological diagnoses; Matsuda K, Suzuki H and Koike K approved the final article.

**Supported by** Ministry of Education, Culture, Sports, Science and Technology of Japan, No. 25134707 and No. 16H01566 (to Matsuda K), and No. 15K14377 (to Tanikawa C); funding from the Tailor-Made Medical Treatment with the BBJ Project from Japan Agency for Medical Research and Development, AMED (from April 2015); and the Ministry of Education, Culture, Sports, Science, and Technology of Japan (from April 2003 to March 2015).

**Corresponding author:** **Osamu Toyoshima, MD, Doctor,** Department of Gastroenterology, Toyoshima Endoscopy Clinic, 6-17-5 Seijo, Setagaya-ku, Tokyo 157-0066, Japan. t@ichou.com

**Received:** May 24, 2020

**Revised:** June 20, 2020

**Accepted:** August 26, 2020

**Published online:** September 14, 2020

**Abstract**

BACKGROUND

Endoscopy-based Kyoto classification for gastritis and pathological topographic distribution of neutrophil infiltration are correlated with gastric cancer risk.

AIM

To investigate the association between Kyoto classification and the topographic distribution of neutrophil activity.

METHODS

Kyoto classification score, ranging from 0 to 8, consisted of atrophy, intestinal metaplasia, enlarged folds, nodularity, and diffuse redness. Neutrophil activity was scored according to the updated Sydney System using biopsy samples obtained from the greater curvature of the corpus and the antrum. The participants were divided into four categories, inactive stomach, antrum-predominant gastritis, pangastritis, and corpus-predominant gastritis, based on the topographic distribution of neutrophil activity. Effects of sex, age, body mass index, drinking habit, smoking habit, family history of gastric cancer, serum *Helicobacter pylori* (*H. pylori*) antibody, and Kyoto score on topography of neutrophil infiltration were analyzed.

RESULTS

A total of 327 patients (comprising 50.7% women, with an average age of 50.2 years) were enrolled in this study. *H. pylori* infection rate was 82.9% with a mean Kyoto score of 4.63. The Kyoto score was associated with the topographic distribution of neutrophil activity. Kyoto scores were significantly higher in the order of inactive stomach, antrum-predominant gastritis, pangastritis, and corpus-predominant gastritis (3.05, 4.57, 5.21, and 5.96, respectively). Each individual score of endoscopic findings (*i.e*., atrophy, intestinal metaplasia, enlarged folds, nodularity, and diffuse redness) was correlated with the topographic distribution of neutrophil activity. On multivariate analysis, the Kyoto score, age, and serum *H. pylori* antibody were independently associated with the topographic distribution of neutrophil activity.

CONCLUSION

The Kyoto classification score was associated with the topographic distribution of neutrophil activity.

**Key words:** Kyoto classification; *Helicobacter pylori*; Neutrophil activity; Updated Sydney System; Gastritis; Gastric cancer; Endoscopy; Pathology

Toyoshima O, Nishizawa T, Yoshida S, Sakaguchi Y, Nakai Y, Watanabe H, Suzuki H, Tanikawa C, Matsuda K, Koike K. Endoscopy-based Kyoto classification score of gastritis related to pathological topography of neutrophil activity. *World J Gastroenterol* 2020; 26(34): 5146-5155

URL: https://www.wjgnet.com/1007-9327/full/v26/i34/5146.htm

DOI: https://dx.doi.org/10.3748/wjg.v26.i34.5146

**Core tip:** We investigated the association between endoscopy-based Kyoto classification of gastritis and pathologically topographic distribution of neutrophil activity which related to gastric cancer risk. Kyoto classification score is consisted of atrophy, intestinal metaplasia, enlarged folds, nodularity, and diffuse redness. The subjects were divided into four categories, inactive stomach, antrum-predominant gastritis, pangastritis, and corpus-predominant gastritis, based on distribution of neutrophil activity. Kyoto scores were higher in the order of inactive stomach, antrum-predominant gastritis, pangastritis, and corpus-predominant gastritis. On multivariate analysis, Kyoto score was independently associated with topographic distribution of neutrophil activity. In conclusion, Kyoto classification score was associated with gastric cancer risk.

**INTRODUCTION**

Stomach cancer is the third leading cause of cancer-related mortality in both sexes worldwide according to the 2018 GLOBOCAN estimates[1]. Thus, the key to obtaining a significant effect on the prognosis of gastric adenocarcinoma and its economic burden is to accurately identify at-risk individuals[2-5].

The updated Sydney System is the most widely accepted method for the histological classification and grading of gastritis[6-8]; it can also assess pathologic features related to *Helicobacter pylori* (*H. pylori*) infection such as neutrophil activity, chronic inflammation, atrophy, intestinal metaplasia, and gastric cancer[9]. Neutrophil activity is measured by continuing acute inflammation and is linked to tissue damage. The density of intraepithelial neutrophils is correlated with the extent of mucosal damage and intensity of *H. pylori* infection[6,10]. The topographic distribution of neutrophil activity has been reportedly associated with gastric cancer development[11].

Endoscopy-led risk stratification is preferable since pathology-based evaluation is more invasive. The endoscopic Kyoto classification of gastritis was advocated by the Japan Gastroenterological Endoscopy Society in 2013. The Kyoto classification was established with the aim to unify the endoscopic diagnosis of gastritis in daily practice and match it with the histological diagnosis. The Kyoto classification score consisted of scores in gastric atrophy, intestinal metaplasia, enlarged folds, nodularity, and diffuse redness[12]. Several studies have revealed the association of the Kyoto score with *H. pylori* infection[13-17] and gastric cancer risk[18-20]; however, the consistency of the Kyoto score with pathological findings has not been clarified. Therefore, this study aimed to investigate the relationship between the Kyoto score and pathological findings.

**MATERIALS AND METHODS**

***Study design and subjects***

This study was approved by the institutional review board at the Institute of Medical Science, University of Tokyo on September 21, 2013 (approval No. 25-34-0921). All participants provided written informed consent.

This cohort study consisted of participants who underwent esophagogastroduodenoscopy at Toyoshima Endoscopy Clinic from December 2013 to January 2016. Esophagogastroduodenoscopies were performed either for screening, evaluation of present symptoms, or surveillance of previous esophagogastroduodenal diseases. Inclusion criteria were as follows: patients aged ≥ 20 years without history of gastric neoplasia, surgical gastrectomy, or *H. pylori* eradication. Exclusion criteria involved a withdrawal of concent.

Demographic characteristics including age, sex, body mass index, smoking history, habitual drinking, and first-degree family history of gastric cancer were obtained[21].A score of at least 400 on the Brinkman index was defined as positive smoking history. Consumption of at least one alcoholic drink per day was defined as habitual drinking.

***Endoscopy-based Kyoto classification score***

Endoscopic Kyoto classification score for gastritis, from 0 to 8, is based on the total scores of the following five endoscopic findings: atrophy, intestinal metaplasia, enlarged folds, nodularity, and diffuse redness. A high score represents increased risk for gastric cancer and *H. pylori* infection[12].

Pathological atrophy is defined as the loss of normal glandular tissue of the gastric mucosa. Endoscopic atrophy was classified according to the extent of mucosal atrophy, as described by Kimura *et al*[22] and Takemoto *et al*[23]. Non-atrophy and C1 were scored as Atrophy score 0, C2 and C3 as Atrophy score 1, and O1 to O3 as Atrophy score 2.

Pathological intestinal metaplasia is defined as a phenotypic change from the normal epithelial cell of the gastric mucosa to an intestinal phenotype. Endoscopically, intestinal metaplasia typically appears as grayish-white and slightly elevated plaques surrounded by mixed patchy pink and pale areas of the mucosa, forming an irregular uneven surface. Villous appearance, whitish mucosa, and rough mucosal surface are useful indicators for endoscopic diagnosis of intestinal metaplasia[24]. Intestinal metaplasia score 0 is defined as the absence of intestinal metaplasia; intestinal metaplasia score 1 as the presence of intestinal metaplasia within the antrum; and intestinal metaplasia score 2 as intestinal metaplasia extending into the corpus. The Intestinal metaplasia score is calculated based on the diagnosis using the white light imaging. Intestinal metaplasia diagnosis based on image-enhanced endoscopy and chromo-endoscopy is not included in the Intestinal metaplasia score.

An enlarged fold is defined as a width of ≥ 5 mm that is not flattened or is only partially flattened by stomach insufflation. The absence and presence of enlarged folds were scored as Enlarged folds score 0 and 1, respectively.

Nodular gastritis is characterized by a miliary pattern resembling “goose flesh” mainly located in the antrum. The absence and presence of nodularity was scored as Nodularity score 0 and 1, respectively.

Diffuse redness refers to uniform redness with continuous expansion observed in non-atrophic mucosa mainly in the corpus[22]. Regular arrangement of collecting venules (RAC) is a condition where collecting venules are arranged in the corpus. From a distance, it appears like numerous dots; up close, it has the appearance of a regular pattern of starfish-like shapes. The absence of diffuse redness, presence of mild diffuse redness or diffuse redness with RAC, and severe diffuse redness or diffuse redness without RAC were scored as Diffuse redness score 0, 1, and 2, respectively.

***Pathology (topographic distribution of neutrophil activity)***

We obtained biopsy specimens from two sites, the greater curvature of the corpus and the antrum[25]. One experienced gastrointestinal pathologist diagnosed neutrophil activity score based on the updated Sydney System in hematoxylin and eosin staining. Neutrophil infiltration was graded on a scale of 0-3 (none, 0; mild, 1; moderate, 2; severe, 3).

Based on the topographic distribution of neutrophil infiltration, the patients were divided into four categories: “inactive stomach,” “antrum-predominant gastritis,” “pangastritis,” and “corpus-predominant gastritis.” When neutrophil activity was null for the antrum and the corpus, the diagnosis was “inactive stomach.” When the antrum score was larger than that of the corpus, the diagnosis was “antrum-predominant gastritis.” When neutrophil activity was positive, and the antrum score was equal to that of the corpus, the diagnosis was “pangastritis.” When the corpus score was larger than that of the antrum, the diagnosis was “corpus-predominant gastritis[11,26].”

***The serum anti-H. pylori antibody***

Patients’ blood samples were obtained on the day of esophagogastroduodenoscopy. The serum antibody titer was measured by an enzyme-linked immunoassay kit using antigens derived from Japanese individuals: E-plate Eiken *H. pylori* antibody II kit (Eiken Chemical, Tokyo, Japan). We defined a cut-off value of 10 U/mL was identified for *H. pylori* positivity as the manufacturer recommended[13-15].

***Statistical analysis***

We tested the association between the Kyoto classification score, including atrophy, intestinal metaplasia, enlarged folds, nodularity, and diffuse redness score, and the four categories of topographic distribution of neutrophil activity by Kruskal–Wallis and Steel–Dwass analysis. A multinomial logistic regression analysis was performed using the four categories of gastritis as objective variables. Sex, age, body mass index, drinking, smoking habit, first-degree family history of gastric cancer, serum *H. pylori* antibody, and the Kyoto score were used as explanatory variables. A *P* value of < 0.05 was defined as statistical significance. Calculations were carried out using the statistical software Ekuseru-Toukei 2015 (Social Survey Research Information Co., Ltd., Tokyo, Japan).

**RESULTS**

A total of 327 patients (comprising 50.7% women, with an average age of 50.2 years) were enrolled in this study. *H. pylori* infection rate was 82.9% with a mean Kyoto score of 4.63 (Table 1).

The Kyoto score was associated with the topographic distribution of neutrophil activity (*P* < 0.001 calculated by Kruskal–Wallis test). Kyoto scores were significantly higher in the order of inactive stomach, antrum-predominant gastritis, pangastritis, and corpus-predominant gastritis (3.05, 4.57, 5.21, and 5.96, respectively; Figure 1). Table 2 shows that each individual score of endoscopic findings (*i.e*., atrophy, intestinal metaplasia, enlarged folds, nodularity, and diffuse redness) was correlated with the topographic distribution of neutrophil activity. On multivariate analysis, the Kyoto score, age, and serum *H. pylori* antibody were independently associated with the topographic distribution of neutrophil activity (Table 3).

**DISCUSSION**

Our study revealed that the Kyoto score was associated with the topographic distribution of neutrophil activity. Uemura *et al*[11] reported the significance of gastritis topography, and relative risks of gastric cancer for pangastritis and corpus-predominant gastritis were 15.6 and 34.5, respectively, as compared with antrum-predominant gastritis. Namely, the risk of gastric cancer increased in the order of antrum-predominant gastritis, pangastritis, and corpus-predominant gastritis. In this study, Kyoto score also increased in a similar order.

Our data also showed that age, endoscopic atrophy score, and endoscopic intestinal metaplasia score increased in the order of pathologically antrum-predominant active gastritis, pangastritis, and corpus-predominant gastritis. Correa’s cascade in *H. pylori*-associated gastritis follows the following consecutive steps: (1) Normal gastric mucosa; (2) nonatrophic antrum-predominant active gastritis; (3) atrophy; (4) intestinal metaplasia; (5) dysplasia; and (6) cancer[27]. Atrophic gastritis progresses from the antrum to the corpus[22,23]. In the early phase of atrophic gastritis, neutrophils are mainly infiltrated in the antrum. This condition could correspond to antrum-predominant active gastritis. When atrophic gastritis progresses from the antrum to the corpus, neutrophil infiltration in antrum and corpus would be similar. This condition could correspond to pangastritis. Along with the atrophic gastritis progression, intestinal metaplasia occurs, especially in the antrum. Since intestinal metaplasia could be a harsh environment for *H. pylori*, topographic distribution of *H. pylori* could alter from the antrum to the corpus[28]. The density of *H. pylori* was also correlated with neutrophil activity[10,29-31]. After the emergence of antral intestinal metaplasia, neutrophil activity decreases in the antrum, and the status could be categorized as corpus-predominant gastritis. Namely, pathologically active gastritis could progress in the order of antrum-predominant gastritis, pangastritis, and corpus-predominant gastritis (Figure 2). Imagawa *et al*[32] also suggested that gastritis topography changes in the order of antrum-predominant gastritis, pangastritis, and corpus-predominant gastritis as age advances. In our study, endoscopic atrophy and intestinal metaplasia were associated with the development of pathologically active gastritis.

A number of studies have shown that pathological topography of neutrophil infiltration was correlated with gastric cancer risk[32]. Sakitani *et al*[33] demonstrated that neutrophil infiltration in the corpus was a risk factor for gastric cancer, especially for the diffuse-type cancer. Matsuhisa *et al*[34] showed that among *H. pylori*-positive patients, corpus-predominant gastritis was common in elderly Japanese and Chinese whose prevalence of gastric cancer were high, whereas antrum-predominant gastritis was prevalent in Thailand and Vietnam, which had low incidence of gastric cancer. We previously reported that corpus-predominant gastritis and pangastritis were associated with the risk allele of *Prostate Stem Cell Antigen* gene, a gastric cancer-related single nucleotide polymorphism. The patients with corpus-predominant gastritis and the pangastritis had low expression of *Prostate Stem Cell Antigen* in the gastric mucosa, as did the stomach cancer patients did[26]. It has also been reported that the presence of neutrophil infiltration in the corpus is related to metachronous gastric cancer[35] and that activated neutrophils generate reactive oxygen and nitrogen species, which are mutagenic and carcinogenic[36,37]. Although gastritis topography for gastric cancer risk has ample evidence, Kyoto score for gastric cancer risk has not been fully assessed yet[18,38]. Thus, this study provides evidentiary support that Kyoto score is useful for assessing gastric cancer risk.

This study has several limitations. First, this was a retrospective, single-center study. Second, interobserver agreement and reproducibility of the Kyoto classification have not been demonstrated. Third, the category of inactive stomach included subjects who had not been infected with *H. pylori* and those with spontaneous disappearance of *H. pylori*. Since cancer risks of the two types of subjects are markedly different, it is advisable that these patients will be investigated separately in the future[39,40].

**CONCLUSION**

In conclusion, the Kyoto classification score was associated with topographic distribution of neutrophil activity.

**ARTICLE HIGHLIGHTS**

***Research background***

The pathological topographic distribution of neutrophil activity in the gastric mucosa correlates to gastric cancer development. Endoscopy-based Kyoto classification of gastritis has also been reported to be associated with gastric cancer risk.

***Research motivation***

The consistency of the Kyoto classification score with the topographic distribution of neutrophil activity was not clear.

***Research objectives***

To investigate the association between endoscopic findings of gastritis based on the Kyoto classification and pathological topography of neutrophil activity.

***Research methods***

This study consisted of participants who underwent esophagogastroduodenoscopy at the Toyoshima Endoscopy Clinic from December 2013 to January 2016. We obtained two-points biopsy samples from the greater curvature of corpus and antrum. Based on the pathological topographic distribution of neutrophil activity, the subjects were divided into four categories: inactive stomach, antrum-predominant gastritis, pangastritis, and corpus-predominant gastritis. We tested the association between the Kyoto classification score, including atrophy, intestinal metaplasia, enlarged folds, nodularity, and diffuse redness score, and the four categories of topographic distribution of neutrophil activity.

***Research results***

We enrolled 327 patients. The Kyoto scores were significantly higher in the order of inactive stomach, antrum-predominant gastritis, pangastritis, and corpus-predominant gastritis (3.05, 4.57, 5.21, and 5.96, respectively). Especially, atrophy score and intestinal metaplasia score were correlated with the topographic distribution of neutrophil activity. On multivariate analysis, the Kyoto score, age, and serum *Helicobacter pylori* antibody were independently associated with the topographical distribution of neutrophil activity.

***Research conclusions***

Endoscopic findings of gastritis based on the Kyoto classification were associated with the pathological topographic distribution of neutrophil activity and showed the stepwise increase in the order of inactive stomach, antrum-predominant gastritis, pangastritis, and corpus-predominant gastritis.

***Research perspectives***

Our study supports the hypothesis that endoscopic findings based on the Kyoto score are useful for the assessment of gastric cancer risk. However, further studies are warranted to clarify the association between the Kyoto classification of gastritis and gastric cancer risk.

**REFERENCES**

1 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 **Banks M**, Graham D, Jansen M, Gotoda T, Coda S, di Pietro M, Uedo N, Bhandari P, Pritchard DM, Kuipers EJ, Rodriguez-Justo M, Novelli MR, Ragunath K, Shepherd N, Dinis-Ribeiro M. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. *Gut* 2019; **68**: 1545-1575 [PMID: 31278206 DOI: 10.1136/gutjnl-2018-318126]

3 **Quach DT**, Hiyama T, Gotoda T. Identifying high-risk individuals for gastric cancer surveillance from western and eastern perspectives: Lessons to learn and possibility to develop an integrated approach for daily practice. *World J Gastroenterol* 2019; **25**: 3546-3562 [PMID: 31367156 DOI: 10.3748/wjg.v25.i27.3546]

4 **Negovan A**, Iancu M, Fülöp E, Bănescu C. *Helicobacter pylori* and cytokine gene variants as predictors of premalignant gastric lesions. *World J Gastroenterol* 2019; **25**: 4105-4124 [PMID: 31435167 DOI: 10.3748/wjg.v25.i30.4105]

5 **Sugimoto M**, Murata M, Yamaoka Y. Chemoprevention of gastric cancer development after *Helicobacter pylori* eradication therapy in an East Asian population: Meta-analysis. *World J Gastroenterol* 2020; **26**: 1820-1840 [PMID: 32351296 DOI: 10.3748/wjg.v26.i15.1820]

6 **Dixon MF**, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* 1996; **20**: 1161-1181 [PMID: 8827022 DOI: 10.1148/radiology.203.2.434]

7 **Dinis-Ribeiro M**, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, Pereira C, Pimentel-Nunes P, Correia R, Ensari A, Dumonceau JM, Machado JC, Macedo G, Malfertheiner P, Matysiak-Budnik T, Megraud F, Miki K, O'Morain C, Peek RM, Ponchon T, Ristimaki A, Rembacken B, Carneiro F, Kuipers EJ; European Society of Gastrointestinal Endoscopy; European Helicobacter Study Group; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). *Endoscopy* 2012; **44**: 74-94 [PMID: 22198778 DOI: 10.1055/s-0031-1291491]

8 **Matsuo Y**, Kido Y, Akada J, Shiota S, Binh TT, Trang TT, Dung HD, Tung PH, Tri TD, Thuan NP, Tam LQ, Nam BC, Khien VV, Yamaoka Y. Novel CagA ELISA exhibits enhanced sensitivity of *Helicobacter pylori* CagA antibody. *World J Gastroenterol* 2017; **23**: 48-59 [PMID: 28104980 DOI: 10.3748/wjg.v23.i1.48]

9 **Chey WD**, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. *Am J Gastroenterol* 2007; **102**: 1808-1825 [PMID: 17608775 DOI: 10.1111/j.1572-0241.2007.01393.x]

10 **Fiocca R**, Villani L, Luinetti O, Gianatti A, Perego M, Alvisi C, Turpini F, Solcia E. Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: a morphological approach to the study of ulcerogenesis in man. *Virchows Arch A Pathol Anat Histopathol* 1992; **420**: 489-498 [PMID: 1609509 DOI: 10.1007/bf01600253]

11 **Uemura N**, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med* 2001; **345**: 784-789 [PMID: 11556297 DOI: 10.1056/NEJMoa001999]

12 **Toyoshima O**, Nishizawa T, Koike K. Endoscopic Kyoto classification of *Helicobacter pylori* infection and gastric cancer risk diagnosis. *World J Gastroenterol* 2020; **26**: 466-477 [PMID: 32089624 DOI: 10.3748/wjg.v26.i5.466]

13 **Toyoshima O**, Nishizawa T, Arita M, Kataoka Y, Sakitani K, Yoshida S, Yamashita H, Hata K, Watanabe H, Suzuki H. *Helicobacter pylori* infection in subjects negative for high titer serum antibody. *World J Gastroenterol* 2018; **24**: 1419-1428 [PMID: 29632423 DOI: 10.3748/wjg.v24.i13.1419]

14 **Toyoshima O**, Nishizawa T, Sakitani K, Yamakawa T, Takahashi Y, Yamamichi N, Hata K, Seto Y, Koike K, Watanabe H, Suzuki H. Serum anti-*Helicobacter pylori* antibody titer and its association with gastric nodularity, atrophy, and age: A cross-sectional study. *World J Gastroenterol* 2018; **24**: 4061-4068 [PMID: 30254410 DOI: 10.3748/wjg.v24.i35.4061]

15 **Nishizawa T**, Sakitani K, Suzuki H, Yamakawa T, Takahashi Y, Yamamichi N, Watanabe H, Seto Y, Koike K, Toyoshima O. A combination of serum anti-*Helicobacter pylori* antibody titer and Kyoto classification score could provide a more accurate diagnosis of *H pylori*. *United European Gastroenterol J* 2019; **7**: 343-348 [PMID: 31019702 DOI: 10.1177/2050640619825947]

16 **Yoshii S**, Mabe K, Watano K, Ohno M, Matsumoto M, Ono S, Kudo T, Nojima M, Kato M, Sakamoto N. Validity of endoscopic features for the diagnosis of Helicobacter pylori infection status based on the Kyoto classification of gastritis. *Dig Endosc* 2020; **32**: 74-83 [PMID: 31309632 DOI: 10.1111/den.13486]

17 **Toyoshima O**, Nishizawa T, Sakitani K, Yamakawa T, Takahashi Y, Kinoshita K, Torii A, Yamada A, Suzuki H, Koike K. Helicobacter pylori eradication improved the Kyoto classification score on endoscopy. *JGH Open* 2020 [DOI: 10.1002/jgh3.12360]

18 **Sugimoto M**, Ban H, Ichikawa H, Sahara S, Otsuka T, Inatomi O, Bamba S, Furuta T, Andoh A. Efficacy of the Kyoto Classification of Gastritis in Identifying Patients at High Risk for Gastric Cancer. *Intern Med* 2017; **56**: 579-586 [PMID: 28321054 DOI: 10.2169/internalmedicine.56.7775]

19 **Nishizawa T**, Toyoshima O, Kondo R, Sekiba K, Tsuji Y, Ebinuma H, Suzuki H, Tanikawa C, Matsuda K, Koike K. The simplified Kyoto Classification Score is Consistent with the ABC Method of Classification. *J Clin Biochem Nutr* 2020 [DOI: 10.3164/jcbn.20-41]

20 **Toyoshima O**, Matsuda K, Nishizawa T, Sekiba K, Matsuno T, Kondo R, Watanabe H, Suzuki H, Tanikawa C, Koike K. A single nucleotide polymorphism in Prostate Stem Cell Antigen is associated with endoscopic grading in Kyoto classification of gastritis. *J Clin Biochem Nutr* 2020 [DOI: [10.3164/jcbn.20-67](https://doi.org/10.3164/jcbn.20-67)]

21 **Nishizawa T**, Suzuki H, Sakitani K, Yamashita H, Yoshida S, Hata K, Kanazawa T, Fujiwara N, Kanai T, Yahagi N, Toyoshima O. Family history is an independent risk factor for the progression of gastric atrophy among patients with *Helicobacter pylori* infection. *United European Gastroenterol J* 2017; **5**: 32-36 [PMID: 28405319 DOI: 10.1177/2050640616642341]

22 **Kimura K**, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. *Endoscopy* 1969; **3**: 87-97 [DOI: 10.1055/s-0028-1098086]

23 **Toyoshima O**, Yamaji Y, Yoshida S, Matsumoto S, Yamashita H, Kanazawa T, Hata K. Endoscopic gastric atrophy is strongly associated with gastric cancer development after Helicobacter pylori eradication. *Surg Endosc* 2017; **31**: 2140-2148 [PMID: 27604367 DOI: 10.1007/s00464-016-5211-4]

24 **Fukuta N**, Ida K, Kato T, Uedo N, Ando T, Watanabe H, Shimbo T; Study Group for Investigating Endoscopic Diagnosis of Gastric Intestinal Metaplasia. Endoscopic diagnosis of gastric intestinal metaplasia: a prospective multicenter study. *Dig Endosc* 2013; **25**: 526-534 [PMID: 23363394 DOI: 10.1111/den.12032]

25 **Toyoshima O**, Nishizawa T, Sakitani K, Yamakawa T, Watanabe H, Yoshida S, Nakai Y, Hata K, Ebinuma H, Suzuki H, Koike K. Nodularity-like appearance in the cardia: novel endoscopic findings for *Helicobacter pylori* infection. *Endosc Int Open* 2020; **8**: E770-E774 [PMID: 32490162 DOI: 10.1055/a-1136-9890]

26 **Toyoshima O**, Tanikawa C, Yamamoto R, Watanabe H, Yamashita H, Sakitani K, Yoshida S, Kubo M, Matsuo K, Ito H, Koike K, Seto Y, Matsuda K. Decrease in *PSCA* expression caused by *Helicobacter pylori* infection may promote progression to severe gastritis. *Oncotarget* 2018; **9**: 3936-3945 [PMID: 29423095 DOI: 10.18632/oncotarget.23278]

27 **Correa P**, Houghton J. Carcinogenesis of Helicobacter pylori. *Gastroenterology* 2007; **133**: 659-672 [PMID: 17681184 DOI: 10.1053/j.gastro.2007.06.026]

28 **Shi H**, Xiong H, Qian W, Lin R. Helicobacter pylori infection progresses proximally associated with pyloric metaplasia in age-dependent tendency: a cross-sectional study. *BMC Gastroenterol* 2018; **18**: 158 [PMID: 30373520 DOI: 10.1186/s12876-018-0883-y]

29 **Yamamura F**, Yoshikawa N, Akita Y, Mitamura K, Miyasaka N. Relationship between Helicobacter pylori infection and histologic features of gastritis in biopsy specimens in gastroduodenal diseases, including evaluation of diagnosis by polymerase chain reaction assay. *J Gastroenterol* 1999; **34**: 461-466 [PMID: 10452678 DOI: 10.1007/s005350050297]

30 **Kalebi A**, Rana F, Mwanda W, Lule G, Hale M. Histopathological profile of gastritis in adult patients seen at a referral hospital in Kenya. *World J Gastroenterol* 2007; **13**: 4117-4121 [PMID: 17696233 DOI: 10.3748/wjg.v13.i30.4117]

31 **Fu H**, Ma Y, Yang M, Zhang C, Huang H, Xia Y, Lu L, Jin W, Cui D. Persisting and Increasing Neutrophil Infiltration Associates with Gastric Carcinogenesis and E-cadherin Downregulation. *Sci Rep* 2016; **6**: 29762 [PMID: 27412620 DOI: 10.1038/srep29762]

32 **Imagawa S**, Yoshihara M, Ito M, Yoshida S, Wada Y, Tatsugami M, Takamura A, Tanaka S, Haruma K, Chayama K. Evaluation of gastric cancer risk using topography of histological gastritis: a large-scaled cross-sectional study. *Dig Dis Sci* 2008; **53**: 1818-1823 [PMID: 17999184 DOI: 10.1007/s10620-007-0077-x]

33 **Sakitani K**, Hirata Y, Watabe H, Yamada A, Sugimoto T, Yamaji Y, Yoshida H, Maeda S, Omata M, Koike K. Gastric cancer risk according to the distribution of intestinal metaplasia and neutrophil infiltration. *J Gastroenterol Hepatol* 2011; **26**: 1570-1575 [PMID: 21575058 DOI: 10.1111/j.1440-1746.2011.06767.x]

34 **Matsuhisa T**, Matsukura N, Yamada N. Topography of chronic active gastritis in Helicobacter pylori-positive Asian populations: age-, gender-, and endoscopic diagnosis-matched study. *J Gastroenterol* 2004; **39**: 324-328 [PMID: 15168242 DOI: 10.1007/s00535-003-1329-y]

35 **Sugimoto T**, Yamaji Y, Sakitani K, Isomura Y, Yoshida S, Yamada A, Hirata Y, Ogura K, Okamoto M, Koike K. Neutrophil infiltration and the distribution of intestinal metaplasia is associated with metachronous gastric cancer following endoscopic submucosal dissection. *Can J Gastroenterol Hepatol* 2015; **29**: 321-325 [PMID: 26069891 DOI: 10.1155/2015/950734]

36 **Cerutti PA**. Prooxidant states and tumor promotion. *Science* 1985; **227**: 375-381 [PMID: 2981433 DOI: 10.1126/science.2981433]

37 **Tamir S**, Tannenbaum SR. The role of nitric oxide (NO.) in the carcinogenic process. *Biochim Biophys Acta* 1996; **1288**: F31-F36 [PMID: 8876631 DOI: 10.1016/0304-419x(96)00021-2]

38 **Shichijo S**, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Koike K. Association between gastric cancer and the Kyoto classification of gastritis. *J Gastroenterol Hepatol* 2017; **32**: 1581-1586 [PMID: 28217843 DOI: 10.1111/jgh.13764]

39 **Sakitani K**, Nishizawa T, Arita M, Yoshida S, Kataoka Y, Ohki D, Yamashita H, Isomura Y, Toyoshima A, Watanabe H, Iizuka T, Saito Y, Fujisaki J, Yahagi N, Koike K, Toyoshima O. Early detection of gastric cancer after Helicobacter pylori eradication due to endoscopic surveillance. *Helicobacter* 2018; **23**: e12503 [PMID: 29924436 DOI: 10.1111/hel.12503]

40 **Kishikawa H**, Ojiro K, Nakamura K, Katayama T, Arahata K, Takarabe S, Miura S, Kanai T, Nishida J. Previous Helicobacter pylori infection-induced atrophic gastritis: A distinct disease entity in an understudied population without a history of eradication. *Helicobacter* 2020; **25**: e12669 [PMID: 31680399 DOI: 10.1111/hel.12669]

**Footnotes**

**Institutional review board statement:** This study was approved by the institutional review board at the Institute of Medical Science, University of Tokyo on September 21, 2013 (approval No. 25-34-0921).

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent. For full disclosure, the details of the study are published on the home page of Toyoshima Endoscopy Clinic.

**Conflict-of-interest statement:** All other authors have nothing to disclose.

**Data sharing statement:** Not available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** May 24, 2020

**First decision:** June 12, 2020

**Article in press:** August 26, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Rostami K **S-Editor:** Yan JP **L-Editor:** A **P-Editor:** Zhang YL

**Figure Legends**

**手机屏幕截图

描述已自动生成**

**Figure 1 Kyoto score according to the topographic distribution of neutrophil activity.** Box-plots depicting the average Kyoto score. *P* value was calculated using the Steel–Dwass test.

图片包含 标志, 桌子, 橘子, 充满

描述已自动生成

**Figure 2** **Representative images of four categories of gastritis.** A-C: Inactive stomach. A 49-year-old woman. Kyoto score: 3; atrophy score: 1; intestinal metaplasia score: 0; enlarged folds score: 0; nodularity score: 0; diffuse redness score: 2; D-F: Antrum-predominant gastritis. A 37-year-old man. Kyoto score: 4; atrophy score: 1; intestinal metaplasia score: 0; enlarged folds score: 1; nodularity score: 0; diffuse redness score: 2; G-I: Pangastritis. A 45-year-old man. Kyoto score: 5; atrophy score: 1; intestinal metaplasia score: 0; enlarged folds score: 1; nodularity score: 1; diffuse redness score: 2; J-L: Corpus-predominant gastritis. A 51-year-old woman. Kyoto score: 6; atrophy score: 2; intestinal metaplasia score: 2; enlarged folds score: 0; nodularity score: 0; diffuse redness score: 2. Greater curvature of the corpus (A, D, G and J); Lesser curvature of the corpus (B, E, H and K); Antrum (C, F, I and L).

**Table 1 Baseline characteristics of patients**

|  |  |
| --- | --- |
| **Baseline characteristics of patients** | |
| Number | 327 |
| Female sex, % | 50.7 |
| Age, mean (± SD), yr | 50.2 (12.3) |
| Body mass index, mean (± SD), kg/m2 | 22.4 (3.1) |
| Drinking, % | 26.0 |
| Smoking, % | 8.3 |
| Family history of gastric cancer, % | 16.8 |
| Positive *Helicobacter pylori* antibody, % | 82.9 |
| Kyoto score, mean (± SD) | 4.63 (1.89) |
| Atrophy score, mean (± SD) | 1.35 (0.69) |
| Intestinal metaplasia score, mean (± SD) | 0.61 (0.88) |
| Enlarged folds score, mean (± SD) | 0.47 (0.50) |
| Nodularity score, mean (± SD) | 0.40 (0.49) |
| Diffuse redness score, mean (± SD) | 1.71 (0.64) |

**Table 2 Association between Kyoto classification score and the topographic distribution of neutrophil activity**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Inactive stomach** | **Antrum-predominant gastritis** | **Pangastritis** | **Corpus-predominant gastritis** | ***P* value** |
| Atrophy score, mean (± SD) | 1.03 (0.80) | 1.30 (0.64) | 1.46 (0.61) | 1.76 (0.52) | < 0.001 |
| Intestinal metaplasia score, mean (± SD) | 0.53 (0.83) | 0.54 (0.83) | 0.57 (0.88) | 1.36 (0.91) | < 0.001 |
| Enlarged folds score, mean (± SD) | 0.18 (0.39) | 0.54 (0.50) | 0.57 (0.50) | 0.56 (0.51) | < 0.001 |
| Nodularity score, mean (± SD) | 0.27 (0.45) | 0.32 (0.47) | 0.53 (0.50) | 0.28 (0.46) | < 0.001 |
| Diffuse redness score, mean (± SD) | 0.97 (0.85) | 1.83 (0.49) | 1.97 (0.25) | 1.96 (0.20) | < 0.001 |

*P* value was calculated using Kruskal–Wallis test.

**Table 3 Multivariate analysis for the topographic distribution of neutrophil activity**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Inactive stomach** | **Antrum-predominant gastritis** | **Pangastritis** | **Corpus-predominant gastritis** | ***P* value** |
| No. | 73 | 82 | 147 | 25 |  |
| Female sex, % | 50.7 | 42.7 | 52.4 | 48 | 0.646 |
| Age, mean (± SD), yr | 53.6 (14.1) | 46.8 (10.4) | 48.7 (11.3) | 60.4 (10.9) | < 0.001 |
| Body mass index, mean (± SD), kg/m2 | 22.8 (3.1) | 22.9 (3.6) | 22.0 (2.8) | 21.8 (3.2) | 0.254 |
| Drinking, % | 27.4 | 23.2 | 25.2 | 36 | 0.758 |
| Smoking, % | 9.6 | 8.5 | 5.4 | 20 | 0.083 |
| Family history of gastric cancer, % | 13.7 | 18.3 | 15 | 32 | 0.162 |
| Positive *Helicobacter pylori* antibody, % | 45.2 | 92.7 | 95.2 | 88 | < 0.001 |
| Kyoto score, mean (± SD) | 3.05 (2.36) | 4.57 (1.52) | 5.21 (1.35) | 5.96 (1.17) | < 0.001 |

*P* value was calculated using the multinomial logistic regression analysis.